Literature DB >> 6197478

Antigenic structure of hepatitis B surface antigen: identification of the "d" subtype determinant by chemical modification and use of monoclonal antibodies.

D L Peterson, D A Paul, J Lam, I I Tribby, D T Achord.   

Abstract

Hepatitis B surface antigens (HBsAg) of both the adw and ayw subtypes were reductively methylated with formaldehyde in the presence of sodium cyanoborohydride. The effect on antigenicity was determined by radioimmunoassay with monoclonal antibodies specific for seven different antigenic determinants. The reaction was shown to eliminate specifically the "d" antigenic activity of HBsAg/adw and to have no effect on HBsAg/ayw. Moreover, the reaction had only a slight affect on HBsAg/adw at one of the "a" antigenic determinants. The sites of modification were determined and the extent of modification of each site was compared to the loss of "d" antigenic activity. These studies demonstrated that the loss of "d" activity was due to the modification of lysine 122 in HBsAg/adw, and that although the amino terminus and lysine residues 141 and 160 of both HBsAg/adw and HBsAg/ayw are reactive, their modification does not alter any measurable antigenic activity.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6197478

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  20 in total

1.  Neutralization epitope responsible for the hepatitis B virus subtype-specific protection in chimpanzees.

Authors:  Pei Zhang; Mei-Ying W Yu; Richard Venable; Harvey J Alter; J Wai-Kou Shih
Journal:  Proc Natl Acad Sci U S A       Date:  2006-06-06       Impact factor: 11.205

2.  The amino Acid residues at positions 120 to 123 are crucial for the antigenicity of hepatitis B surface antigen.

Authors:  Yongjun Tian; Yang Xu; Zhenhua Zhang; Zhongji Meng; Li Qin; Mengji Lu; Dongliang Yang
Journal:  J Clin Microbiol       Date:  2007-07-03       Impact factor: 5.948

3.  Use of PCR in resolving diagnostic difficulties potentially caused by genetic variation of hepatitis B virus.

Authors:  F J van Deursen; K Hino; D Wyatt; P Molyneaux; P Yates; L A Wallace; B C Dow; W F Carman
Journal:  J Clin Pathol       Date:  1998-02       Impact factor: 3.411

4.  Analysis of cell-associated recombinant hepatitis B surface antigen by flow cytometry.

Authors:  J L Farmer; H E Irace; M Maaba; K Heine
Journal:  Arch Virol       Date:  1989       Impact factor: 2.574

5.  HBsAg subtype distribution among different populations of HBsAg carriers in Spain.

Authors:  J E Echevarría; P León; J A López; A Tenorio; C J Domingo; J M Echevarría
Journal:  Eur J Epidemiol       Date:  1995-02       Impact factor: 8.082

6.  Point mutation in the S gene of hepatitis B virus for a d/y or w/r subtypic change in two blood donors carrying a surface antigen of compound subtype adyr or adwr.

Authors:  H Okamoto; M Imai; F Tsuda; T Tanaka; Y Miyakawa; M Mayumi
Journal:  J Virol       Date:  1987-10       Impact factor: 5.103

7.  Analysis of viral proteins in circulating immune complexes from chronic carriers of hepatitis B virus.

Authors:  K Madalinski; B Burczynska; K H Heermann; A Uy; W H Gerlich
Journal:  Clin Exp Immunol       Date:  1991-06       Impact factor: 4.330

8.  Hybrid hepatitis B virus nucleocapsid bearing an immunodominant region from hepatitis B virus surface antigen.

Authors:  G Borisova; B Arya; A Dislers; O Borschukova; V Tsibinogin; D Skrastina; M A Eldarov; P Pumpens; K G Skryabin; E Grens
Journal:  J Virol       Date:  1993-06       Impact factor: 5.103

9.  Protection of chimpanzees from type B hepatitis by immunization with woodchuck hepatitis virus surface antigen.

Authors:  P J Cote; M Shapiro; R E Engle; H Popper; R H Purcell; J L Gerin
Journal:  J Virol       Date:  1986-12       Impact factor: 5.103

10.  Hepatitis B virus: molecular genotypes and HBeAg serological status among HBV-infected patients in the southeast of Brazil.

Authors:  Priscila A Tonetto; Neiva S L Gonçales; Viviane C Fais; Aline G Vigani; Eduardo S L Gonçales; Adriana Feltrin; Fernando L Gonçales
Journal:  BMC Infect Dis       Date:  2009-09-08       Impact factor: 3.090

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.